How to Read Biotech Cash Runway: The #1 Signal That Predicts Dilution

In biotech investing, cash runway is the single most important metric that separates winners from dilution traps. Unlike revenue-generating companies, most biotech firms burn cash every quarter while waiting for clinical trial results and FDA approvals. Understanding cash runway gives you a critical edge.

What is Cash Runway?

Cash runway measures how many months a company can continue operating at its current burn rate before running out of money. The formula is simple:

Cash Runway (months) = Cash on Hand / Monthly Burn Rate

For biotech companies, you calculate quarterly burn rate from two consecutive 10-Q filings, then divide by 3 to get the monthly figure.

The Danger Zones

Less than 6 months (RED): The company MUST raise money soon. Expect an ATM offering, direct offering, or shelf registration. Stock typically drops 15-30% on the announcement.
6-12 months (YELLOW): Caution zone. The company is likely preparing to raise money. Watch for S-3 filings and shelf registrations as early warning signs.
12+ months (GREEN): The company is funded through its next major catalyst. This removes dilution risk from the equation and lets you focus on the science.

Real Example: Why Cash Runway Matters

Consider two biotech companies, both with Phase 3 data expected in 6 months:

Company A: $500M cash, $40M/quarter burn = 37 months runway. They can wait for data without pressure.
Company B: $30M cash, $15M/quarter burn = 6 months runway. They need to raise money BEFORE the data readout, likely diluting shareholders at the worst possible time.

Company B holders face a brutal choice: sell before the offering (missing potential upside) or hold through dilution (watching their shares lose value even if the trial succeeds).

Warning Signs to Watch

S-3 shelf registration filing: The company is preparing to sell shares. This is the earliest warning.
ATM (At-The-Market) agreement: They can now sell shares directly into the market at any time.
Increasing burn rate: If quarterly burn is accelerating (Phase 3 trials are expensive), runway shrinks faster than expected.
Management vague about funding: If earnings calls avoid cash questions, it is often a red flag.

How BioRadar Tracks This For You

BioRadar automatically calculates cash runway from SEC quarterly filings for every ticker on your watchlist. You will see a color-coded risk gauge (green/yellow/red), the exact cash amount, quarterly burn rate, and offering alerts. Plus, our AI Cash Summary analyzes the latest company announcements to catch recent fundraising that SEC filings have not yet reflected.

Start tracking cash runway for free — add up to 3 biotech tickers to your watchlist.

This article is for educational purposes only and does not constitute financial advice.